查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1824317

2025年全球子宫肌瘤治疗市场报告

Uterine Fibroids Treatment Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

子宫肌瘤治疗市场规模预计将在未来几年强劲成长，到2029年将达到64.3亿美元，复合年增长率为9.8%。预测期内的成长可归因于非侵入性治疗的进步、对生育力保存的日益重视、微创技术的兴起、个人化医疗方法以及合作研发。预测期内的主要趋势包括：更加重视生育力保存治疗、将影像技术融入治疗计划、进行认知和教育活动、根据患者情况量身定制治疗方案以及探索新的治疗标靶。

未来五年9.8%的成长率预测比我们先前的预测略有下降，下降了0.1%。这一下降主要源自于美国与其他国家之间关税的影响。关税上调可能会增加美国患者的负担，因为这会增加从以色列和加拿大进口的磁振造影引导聚焦超音波设备和孕酮调节剂的成本，从而加剧手术延误并增加妇科费用。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，关税上调的影响也可能更加广泛。

子宫肌瘤治疗市场预期成长的原因是女性子宫肌瘤的高发生率。子宫肌瘤是发生在子宫内的非癌症肿瘤，可引起月经过多、骨盆腔疼痛以及膀胱或肠道压迫等症状。子宫肌瘤的治疗包括抑制雌激素和黄体素的产生，停止月经并改善贫血。例如，根据美国国家生物技术资讯中心2022年11月发布的报告，35岁以下女性子宫肌瘤的发生率估计为40-60%，50岁以上女性子宫肌瘤的发生率估计为70-80%。因此，全球子宫肌瘤的流行正在推动子宫肌瘤治疗市场的成长。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球子宫肌瘤治疗：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球子宫肌瘤治疗市场：成长率分析
  • 全球子宫肌瘤治疗市场表现：规模与成长，2019-2024
  • 全球子宫肌瘤治疗市场预测：规模与成长，2024-2029年，2034年
  • 全球子宫肌瘤治疗：总目标市场（TAM）

第六章 市场细分

  • 全球子宫肌瘤治疗市场：依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 浆膜下肌瘤
  • 子宫壁间肌瘤
  • 黏膜下肌瘤
  • 带蒂子宫肌瘤
  • 全球子宫肌瘤治疗市场（依治疗类型、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 荷尔蒙疗法
  • 雄激素
  • 促性腺激素分泌释放激素拮抗剂
  • 子宫动脉栓塞术
  • 子宫肌瘤切除术
  • 子宫切除术
  • 全球子宫肌瘤治疗市场：按最终用户、绩效和预测，2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 门诊手术中心
  • 其他最终用户
  • 全球子宫肌瘤治疗市场：浆膜下肌瘤细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 带蒂浆膜下肌瘤
  • 无蒂浆膜下肌瘤
  • 全球子宫肌瘤治疗市场：按肌壁内肌瘤（按类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 小壁间肌瘤
  • 大型壁间肌瘤
  • 全球子宫肌瘤治疗市场：依黏膜下肌瘤类型细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 带蒂粘膜下肌瘤
  • 无蒂黏膜下肌瘤
  • 全球子宫肌瘤治疗市场：细分：带蒂子宫肌瘤（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 浆膜下带蒂子宫肌瘤
  • 黏膜下带蒂子宫肌瘤

第七章 区域和国家分析

  • 全球子宫肌瘤治疗市场：按地区、结果和预测，2019-2024 年、2024-2029 年、2034 年
  • 全球子宫肌瘤治疗市场：依国家/地区、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 子宫肌瘤治疗市场：竞争格局
  • 子宫肌瘤治疗市场：公司简介
    • Gynesonics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Karl Storz GmbH Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Abbvie Inc.
  • Richard Wolf GmbH
  • CooperSurgical Inc.
  • Olympus Corporation
  • Myovant Sciences GmbH
  • Insightec Ltd.
  • Hologic Inc.
  • Obseva SA
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Stryker Corporation
  • Smith & Nephew plc
  • Minerva Surgical Inc.
  • Ethicon Inc.
  • Cook Medical LLC

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年子宫肌瘤治疗市场：提供新机会的国家
  • 2029年子宫肌瘤治疗市场：细分领域带来新机会
  • 子宫肌瘤治疗市场2029年：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r24576u

Uterine fibroids treatment encompasses procedures aimed at addressing uterine fibroids, which are non-cancerous growths that form in the uterus, potentially leading to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel.

The primary categories of uterine fibroids treatment consist of subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids. Subserosal fibroids, also known as pedunculated fibroids, are benign growths located on the outer uterine wall, directly connected to the uterus. Various treatment options are available, including hormone therapy, androgens, gonadotropin-releasing hormone antagonists, uterine artery embolization, myomectomy, and hysterectomy. These treatments cater to diverse end-users such as hospitals, ambulatory surgical centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The uterine fibroid treatment market research report is one of a series of new reports from The Business Research Company that provides uterine fibroid treatment market statistics, including uterine fibroid treatment industry global market size, regional shares, competitors with a uterine fibroid treatment market share, detailed uterine fibroid treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid treatment industry. This uterine fibroid treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The uterine fibroids treatment market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.43 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased incidence of uterine fibroids, advancements in diagnostic techniques, rising awareness and education, impact on quality of life, evolution of minimally invasive procedures.

The uterine fibroids treatment market size is expected to see strong growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in non-invasive treatment, increasing emphasis on fertility preservation, rise in minimally invasive techniques, personalized medicine approaches, collaborative research and development. Major trends in the forecast period include rising focus on fertility-preserving treatments, integration of imaging technologies in treatment planning, increasing awareness and education initiatives, customized treatment plans based on patient profiles, exploration of novel therapeutic targets.

The forecast of 9.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of Magnetic resonance imaging -guided focused ultrasound systems and progesterone modulators sourced from Israel and Canada, exacerbating surgical delays and increasing gynecology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the uterine fibroids treatment market is attributed to the high prevalence of uterine fibroids among women. Uterine fibroids, non-cancerous growths in the uterus, can lead to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel. Uterine fibroids treatment involves blocking estrogen and progesterone production, ceasing menstruation, and improving anemia. For example, a November 2022 report from the National Centre for Biotechnology Information revealed an estimated incidence of uterine fibroids ranging from 40 to 60% among women under 35 and 70 to 80% among women over 50. Thus, the widespread prevalence of uterine fibroids worldwide propels the uterine fibroids treatment market's growth.

The expected rise in healthcare expenditure is set to drive the uterine fibroids treatment market. Healthcare expenditure denotes the total financial resources allocated by a country, government, organization, or individual for healthcare-related goods and services within a specific timeframe. Increased healthcare expenditure supports the development and adoption of advanced uterine fibroids treatment options, including minimally invasive procedures such as uterine artery embolization or magnetic resonance-guided focused ultrasound surgery. For instance, in 2022, Poland's healthcare expenditure reached PLN 205.6 billion ($50.99 billion), representing 6.7% of GDP, a growth of about PLN 36.1 billion ($8.95 billion) from 2021. Hence, the escalating healthcare expenditure contributes to the uterine fibroids treatment market's expansion.

Product innovations are emerging as a significant trend in the uterine fibroid treatment market. Companies in this sector are implementing innovative solutions to maintain their competitive edge. For example, in September 2024, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched YSELTY, a new treatment for uterine fibroids that represents a major advancement in women's healthcare. YSELTY provides a non-hormonal treatment option with flexible dosing tailored to individual patient needs, especially for those experiencing severe fibroid symptoms. As a GnRH receptor antagonist, YSELTY works by inhibiting gonadotropin-releasing hormone at its pituitary receptors, thereby reducing estrogen production and effectively alleviating symptoms like bleeding and pain.

Significant players in the uterine fibroids treatment market are directing their efforts toward developing minimally invasive procedures (MIPs) for addressing uterine fibroids. Minimally invasive procedures involve medical interventions or surgeries that cause minimal disruption to the body's normal structure and function. These procedures aim to alleviate symptoms such as heavy menstrual bleeding and pelvic pain while reducing recovery times and preserving reproductive options. As an illustration, Humber River Hospital in Canada launched the use of the Acessa ProVu system in November 2022. This medical technology employs monopolar radiofrequency (RF) energy through a disposable Handpiece for percutaneous, laparoscopic coagulation, and ablation of soft tissue, including the treatment of symptomatic uterine fibroids.

In January 2022, Hologic Inc., a US-based medical technology company, acquired Acessa Health for $80 million, enhancing Hologic's presence in the gynecological surgical space. Acessa Health, a US-based biotechnology company, specializes in developing minimally invasive, uterine-sparing devices designed to treat women suffering from symptomatic fibroids.

Major companies operating in the uterine fibroids treatment market include Gynesonics Inc., Medtronic plc, Boston Scientific Corporation, Karl Storz GmbH, Pfizer Inc., Abbvie Inc., Richard Wolf GmbH, CooperSurgical Inc., Olympus Corporation, Myovant Sciences GmbH, Insightec Ltd., Hologic Inc., Obseva SA, Eli Lilly and Company, GlaxoSmithKline plc, Stryker Corporation, Smith & Nephew plc, Minerva Surgical Inc., Ethicon Inc., Cook Medical LLC, C.R. Bard Inc., Biomerics LLC, Visionsense Corp., Halt Medical Inc., Acessa Health Inc., Blue Endo, LiNA Medical ApS, Merit Medical Systems Inc., Allergan plc, Astellas Pharma Inc.

North America was the largest region in the uterine fibroids treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine fibroids treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the uterine fibroids treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The uterine fibroids treatment market includes revenues earned by entities by providing medical, surgical, and radiologically guided therapies available as treatments for uterine fibroids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Uterine Fibroids Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on uterine fibroids treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for uterine fibroids treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The uterine fibroids treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Subserosal Fibroids; Intramural Fibroids; Submucosal Fibroids; Pedunculated Fibroids
  • 2) By Treatment Type: Hormone Therapy; Androgens; Gonadotropin-Releasing Hormone Antagonists; Uterine Artery Embolization; Myomectomy; Hysterectomy
  • 3) By End-Users: Hospitals; Ambulatory Surgical Centers; Other End users
  • Subsegments:
  • 1) By Subserosal Fibroids: Pedunculated Subserosal Fibroids; Non-Pedunculated Subserosal Fibroids
  • 2) By Intramural Fibroids: Small Intramural Fibroids; Large Intramural Fibroids
  • 3) By Submucosal Fibroids: Pedunculated Submucosal Fibroids; Non-Pedunculated Submucosal Fibroids
  • 4) By Pedunculated Fibroids: Subserosal Pedunculated Fibroids; Submucosal Pedunculated Fibroids
  • Companies Mentioned: Gynesonics Inc.; Medtronic plc; Boston Scientific Corporation; Karl Storz GmbH; Pfizer Inc.; Abbvie Inc.; Richard Wolf GmbH; CooperSurgical Inc.; Olympus Corporation; Myovant Sciences GmbH; Insightec Ltd.; Hologic Inc.; Obseva SA; Eli Lilly and Company; GlaxoSmithKline plc; Stryker Corporation; Smith & Nephew plc; Minerva Surgical Inc.; Ethicon Inc.; Cook Medical LLC; C.R. Bard Inc.; Biomerics LLC; Visionsense Corp.; Halt Medical Inc.; Acessa Health Inc.; Blue Endo; LiNA Medical ApS; Merit Medical Systems Inc.; Allergan plc; Astellas Pharma Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Uterine Fibroids Treatment Market Characteristics

3. Uterine Fibroids Treatment Market Trends And Strategies

4. Uterine Fibroids Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Uterine Fibroids Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Uterine Fibroids Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Uterine Fibroids Treatment Market Growth Rate Analysis
  • 5.4. Global Uterine Fibroids Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Uterine Fibroids Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Uterine Fibroids Treatment Total Addressable Market (TAM)

6. Uterine Fibroids Treatment Market Segmentation

  • 6.1. Global Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids
  • 6.2. Global Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Therapy
  • Androgens
  • Gonadotropin-Releasing Hormone Antagonists
  • Uterine Artery Embolization
  • Myomectomy
  • Hysterectomy
  • 6.3. Global Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End users
  • 6.4. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Subserosal Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pedunculated Subserosal Fibroids
  • Non-Pedunculated Subserosal Fibroids
  • 6.5. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Intramural Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Small Intramural Fibroids
  • Large Intramural Fibroids
  • 6.6. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Submucosal Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pedunculated Submucosal Fibroids
  • Non-Pedunculated Submucosal Fibroids
  • 6.7. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Pedunculated Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Subserosal Pedunculated Fibroids
  • Submucosal Pedunculated Fibroids

7. Uterine Fibroids Treatment Market Regional And Country Analysis

  • 7.1. Global Uterine Fibroids Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Uterine Fibroids Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Uterine Fibroids Treatment Market

  • 8.1. Asia-Pacific Uterine Fibroids Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Uterine Fibroids Treatment Market

  • 9.1. China Uterine Fibroids Treatment Market Overview
  • 9.2. China Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Uterine Fibroids Treatment Market

  • 10.1. India Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Uterine Fibroids Treatment Market

  • 11.1. Japan Uterine Fibroids Treatment Market Overview
  • 11.2. Japan Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Uterine Fibroids Treatment Market

  • 12.1. Australia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Uterine Fibroids Treatment Market

  • 13.1. Indonesia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Uterine Fibroids Treatment Market

  • 14.1. South Korea Uterine Fibroids Treatment Market Overview
  • 14.2. South Korea Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Uterine Fibroids Treatment Market

  • 15.1. Western Europe Uterine Fibroids Treatment Market Overview
  • 15.2. Western Europe Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Uterine Fibroids Treatment Market

  • 16.1. UK Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Uterine Fibroids Treatment Market

  • 17.1. Germany Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Uterine Fibroids Treatment Market

  • 18.1. France Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Uterine Fibroids Treatment Market

  • 19.1. Italy Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Uterine Fibroids Treatment Market

  • 20.1. Spain Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Uterine Fibroids Treatment Market

  • 21.1. Eastern Europe Uterine Fibroids Treatment Market Overview
  • 21.2. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Uterine Fibroids Treatment Market

  • 22.1. Russia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Uterine Fibroids Treatment Market

  • 23.1. North America Uterine Fibroids Treatment Market Overview
  • 23.2. North America Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Uterine Fibroids Treatment Market

  • 24.1. USA Uterine Fibroids Treatment Market Overview
  • 24.2. USA Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Uterine Fibroids Treatment Market

  • 25.1. Canada Uterine Fibroids Treatment Market Overview
  • 25.2. Canada Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Uterine Fibroids Treatment Market

  • 26.1. South America Uterine Fibroids Treatment Market Overview
  • 26.2. South America Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Uterine Fibroids Treatment Market

  • 27.1. Brazil Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Uterine Fibroids Treatment Market

  • 28.1. Middle East Uterine Fibroids Treatment Market Overview
  • 28.2. Middle East Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Uterine Fibroids Treatment Market

  • 29.1. Africa Uterine Fibroids Treatment Market Overview
  • 29.2. Africa Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Uterine Fibroids Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Uterine Fibroids Treatment Market Competitive Landscape
  • 30.2. Uterine Fibroids Treatment Market Company Profiles
    • 30.2.1. Gynesonics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Karl Storz GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Uterine Fibroids Treatment Market Other Major And Innovative Companies

  • 31.1. Abbvie Inc.
  • 31.2. Richard Wolf GmbH
  • 31.3. CooperSurgical Inc.
  • 31.4. Olympus Corporation
  • 31.5. Myovant Sciences GmbH
  • 31.6. Insightec Ltd.
  • 31.7. Hologic Inc.
  • 31.8. Obseva SA
  • 31.9. Eli Lilly and Company
  • 31.10. GlaxoSmithKline plc
  • 31.11. Stryker Corporation
  • 31.12. Smith & Nephew plc
  • 31.13. Minerva Surgical Inc.
  • 31.14. Ethicon Inc.
  • 31.15. Cook Medical LLC

32. Global Uterine Fibroids Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Uterine Fibroids Treatment Market

34. Recent Developments In The Uterine Fibroids Treatment Market

35. Uterine Fibroids Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Uterine Fibroids Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Uterine Fibroids Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Uterine Fibroids Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer